Shenzhen JYMed Technology Co., Ltd.

16/12/2024

Del 26 al 30 de agosto de 2024, la planta de producción de API de péptidos de JYMed, Hubei JXBio Pharmaceutical Co., Ltd., aprobó con éxito una inspección in situ realizada por la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA). La inspección abarcó áreas clave como el sistema de calidad, el sistema de producción, el sistema de equipos e instalaciones, los controles de laboratorio y el sistema de gestión de materiales. Esta es la primera inspección de la FDA que completa con éxito la planta de producción de API de péptidos de Hubei JXBio. Según el informe de inspección, los sistemas de calidad y producción de la planta cumplen plenamente con los estándares de la FDA.

JYMed extiende su sincero agradecimiento a su socio estratégico, Rochem International Inc., por su continuo apoyo durante las inspecciones pasadas y presentes de la FDA.

Este logro significa que la planta de producción de péptidos de Hubei JXio cumple con los requisitos de la FDA para sistemas de calidad y producción, lo que la califica para ingresar al mercado estadounidense.

23/09/2024

Acetate produced by Hubei Pharmaceutical Co., Ltd, a subsidiary of Technology Co., Ltd has successfully passed the drug registration inspection.

【Leuprorelin Acetate Market Overview】
Leuprorelin Acetate is an injectable medication used to treat hormone-dependent diseases, with the molecular formula C59H84N16O12•xC2H4O2. It is a gonadotropin-releasing hormone agonist ( ) that works by inhibiting the pituitary-gonadal system. Originally co-developed by AbbVie and Takeda Pharmaceutical, this drug is marketed under different brand names in various countries. In the United States, it is sold under the brand name DEPOT, while in China, it is marketed as Yinatong.

【Clear Process and Well-Defined Roles】
From 2019 to 2022, the pharmaceutical research and development were completed in JYMed, followed by the registration of the API in March 2024, when the acceptance notice was received. The drug registration inspection was passed in August 2024. JYMed Technology Co., Ltd. was responsible for the process development, analytical method development, impurity studies, structure confirmation, and method validation. Hubei JXBio Pharmaceutical Co., Ltd. was in charge of the process validation production, analytical method validation, and stability studies for the API.

【Expanding Market and Growing Demand】
The rising incidence of prostate cancer and uterine fibroids is driving the increased demand for Leuprorelin Acetate. The North American market currently dominates the Leuprorelin Acetate market, with growing healthcare expenditures and high acceptance of new technologies being the primary growth drivers. Simultaneously, the Asian market, particularly China, is also showing strong demand for Leuprorelin Acetate. Due to its effectiveness, global demand for this drug is on the rise, with the market size expected to reach USD 3,946.1 million by 2031, reflecting a compound annual growth rate (CAGR) of 4.86% from 2021 to 2031.

Know more: https://www.peptidejymed.com/news/exciting-news-jymeds-leuprorelin-acetate-passes-drug-registration-inspection

13/06/2024

Visit Peptide at to know more about ! 👋
Date: 19-21st, Jun, 2024
Location: SNIEC, Shanghai, China
Booth No: W4G49

29/05/2024

Eli Lilly‘s diabetes drug hashtag got approvals in China's NMPA this week. This ushers in a new era of competition among global pharma titans in the ever-expanding multi-billion dollar hashtag -1 drug industry, from China to the rest of the world. Now, each pharmaceutical company's forging ahead within this complex industrial landscape is more urgent than ever.

We at hashtag are eager to assist clients around the world in seizing this invaluable opportunity to enhance their company's capabilities and expand their GLP-1 product lines. JYMed plans to apply for Tirzepatide USDMF registration later this year. With JYMed's China's largest peptide hashtag raw material production capability, know-how support, and 30-year peptide industry experience, pharmaceutical enterprise partners could enjoy great advantages such as less R&D investments and highly competitive raw material costs.

25/05/2024

We are thrilled to anounce our first hashtag exihibition in São Paulo, Brasil. As China's largest hashtag manufacturer, hashtag looks forward to discussing so many wonderful opportunites around peptide APIs with our partners for Brazil and LATAM market in general, especially on GLP-1 API products such as hashtag , hashtag , hashtag .

👋 Warm invitation for every valuable friends! We cannot wait for seeing you at our booth A118.

17/04/2024

JYMed’s Peptide Production Plant Passes FDA Inspection Successfully for the Third Time

Nanjing Xingyin Pharmaceutical Group Co., Ltd, a peptide production plant of JYMed, received an on-site inspection by the US FDA from January 15th to 19th, 2024. We want to express our deep gratitude towards JYMed’s 12-year long-term partner Rochem for its great support and assistance along the work.

Based on FDA’s EIR (Establishment Inspection Report) just came out few days ago, we’re excited to announce that the peptide APIs held by JYMed have successfully passeed the FDA inspection. This new achievement indicates that JYMed’s peptides meet the US FDA cGMP requirements in terms of product quality, production environment, facilities, etc, and JYMed once again is qualified for the highly-competitive US market access conditions.

This is the third time JYMed had successfully passed FDA inspection, highlighting its quality management capabilities have once again been acknowledged by the mainstream European and American markets. Such honor further motivates us to be committed to building a high quality, high-standard API production base with legal compliant and characteristic product lines. Through continuous quality updates, technology innovation, and management improvement, JYMed will uphold its standing ground of globalization, keep improving its international comprehensive competitiveness in API production, and strive to deliver high-quality API for clients around the world.

14/03/2024

Bulk Size Stocks Avaailable for Cosmetic Peptide Ingredients：


Tripeptide-1
Copper Peptide
Acetyl Hexapeptide-8
Copper Peptide
Palmitoyl Tripeptide-1
Palmitoyl Pentapeptide-4
Myristoyl Pentapeptide-17
Biotinoyl Tripeptide-1
Palmitoyl Tripeptide -5
Dipeptide Diaminobutyroyl Benzylamide Diacetate
Nonapeptide-1
Palmitoyl Tetrapeptide-7
Acetyl Octapeptide-3
Acetyl Tetrapeptide-5
Acetyl tetrapeptide-15
Palmitoyl Tripeptide-8
Acetyl Tetrapeptide-9
Palmitoyl Hexapeptide-12
Myristoyl Tetrapeptide-12
Myristoyl Hexapeptide-16
Palmitoyl Tripeptide-38
Pentapeptide-3
Pentapeptide-18
Decapeptide-12
Myristoyl Pentapeptide-4
Carnosine
Acetyl Tripeptide-1
Dipeptide-2
Tripeptide-29
Tetrapeptide-3
Tetrapeptide-30
GHRP-6 Hexapeptide-2
Hexapeptide-9
Hexapeptide-10
Hexapeptide-11
Hexapeptide-9
Oligopeptide-68
Acetyl Tetrapeptide-3
Acetyl Tetrapeptide-11
Acetyl Pentapeptide-1
Acetyl Hexapeptide-1,Melitane
Acetyl Heptapeptide-4
Palmitoyl Dipeptide-7
Decorinyl
Dipeptide-4
Arg-Ala
Hexapeptide-3
Myristoyl Hexapeptide-23
Caprooyl Tetrapeptide-3

11/03/2024

Shanghai Cosmetic Ingredients Exihibition
Visit JYMed on site to know more about cosmetic peptide ingredients.

Date：20th-22nd, Mar, 2024
Address: Shanghai World Expo Exhibition and Convention Center(SWEECC)
Booth No: 2W10

01/03/2024

Os serviços de amostra JYMed para a nova API de peptídeo abaixo estão disponíveis:
Tirzepatida/Retatrutida/Mazdutida/Cagrilintida/Survodutida/Icatibant/Linoclotida/Somatostatina/Eptifibatida/Cetrorelix/Etelcalcetida/Plecanatida/Abaloparatida/Goserelina/Histrelina/Pramlintida/Deslorelina/Lanreotida/Ganirelix

Isenção de responsabilidade: todos os produtos são usados apenas para pesquisa e desenvolvimento. A JYMed não assume qualquer responsabilidade por possíveis violações de patentes.

01/03/2024

Se encuentran disponibles los servicios de muestra de JYMed para las siguientes API de péptidos nuevos:
Tirzepatida/Retatrutida/Mazdutida/Cagrilintida/Survodutida/Icatibant/Linoclotida/Somatostatina/Eptifibatida/Cetrorelix/Etelcalcetida/Plecanatida/Abaloparatida/Goserelina/Histrelina/Pramlintida/Deslorelina/Lanreotida/Ganirelix

Descargo de responsabilidad: Todos los productos se utilizan únicamente para I+D. JYMed no asume ninguna responsabilidad por posibles infracciones de patentes.

01/03/2024

JYMed sample services for below new peptide API are available:
Tirzepatide/Retatrutide/Mazdutide/Cagrilintide/Survodutide/Icatibant/Linoclotide/Somatostatin/Eptifibatide/Cetrorelix/Etelcalcetide/Plecanatide/Abaloparatide/Goserelin/Histrelin/Pramlintide/Deslorelin/Lanreotide/Ganirelix

Disclaimer: All products are used for R&D only. JYMed doesn't take any responsibility for potential patent infringement.

22/02/2024

Buena publicación. La tirzepatida, con las marcas Mounjaro y Zepbound, es sin duda el medicamento más esperado en el futuro previsible. La filial de , JXBio, es una de sus pocas etiquetadoras NDC en Estados Unidos. Con capacidad de producción a granel de / , agradecemos su consulta y pedido.

El sector ha experimentado un notable crecimiento en sus ingresos a nivel global. Este aumento está impulsado principalmente por el envejecimiento de la población mundial y la consiguiente demanda de tratamientos médicos.

, la compañía estadounidense, informó un repunte en sus ingresos durante el cuarto trimestre de 2023.

Los protagonistas de estos resultados fueron y , dos productos recién presentados que apoyan a los procesos de reducción de peso y control de la diabetes, respectivamente.